Intralesional use of Bevacizumab in Adult Recurrent Laryngeal Papillomatosis

1. Introduction
Recurrent laryngeal papillomatosis (RLP) is a disease characterized by the development of exophytic proliferative lesions of the connective tissue, covered by epithelium, which affects the mucosa of the airways. The responsible agent is human papillomavirus (HPV) infection, and it has a great predilection for the larynx [1]. The most frequently found viral subtypes are HPV 6 and 11, in 90% of cases. Subtypes 16 and 18 are rarer in children with PLR, but if they are present there is a greater potential for malignancy [2].